Navigation Links
PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124
Date:7/16/2008

data from recently completed Phase 2a studies in adult and pediatric CF patients at the European Cystic Fibrosis Conference. Results from these studies demonstrated statistically significant improvements in the primary outcome measure-nasal potential difference (NPD)-across a variety of age ranges, geographies, and nonsense mutation types. In the three-month, Phase 2a extension study of adult patients, results demonstrated a statistically significant mean decrease [28 percent] in the frequency of cough, one of the most prominent and burdensome CF-related symptoms.

About Cystic Fibrosis

Cystic fibrosis (CF) is a life-threatening genetic disease that causes serious lung infections and digestive complications. According to the Cystic Fibrosis Foundation, CF affects approximately 30,000 adults and children in the United States and nearly 70,000 people worldwide. CF occurs in approximately one of every 3,500 live births, with approximately 1,000 new cases diagnosed each year in the United States. There is a commercially available genetic test to determine if a patient's CF is caused by a nonsense mutation, and it is estimated that nonsense mutations are the cause of CF in approximately 10 percent of patients in the United States. There is currently no available therapy to correct defective CFTR production and function. Instead, available treatments for CF are designed to alleviate the symptoms of the disease. These treatments include chest physical therapy to clear the thick mucus from the lungs, antibiotics to treat lung infections and a mucus-thinning drug designed to reduce the number of lung infections and improve lung function. In addition, the majority of CF patients take pancreatic enzyme supplements to assist with food absorption in digestion. There is a significant unmet medical need for treatments for the underlying cause of CF. More information regarding CF is available through the Cystic Fibrosis Foundation ( '/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
2. Nile Therapeutics Announces Dosing in Phase IIa Study of CD-NP in Heart Failure Patients
3. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
4. Silence Therapeutics Announces Board Changes
5. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
6. Data Presented at American Headache Societys Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics Tezampanel
7. TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
8. CV Therapeutics Announces Archives of Internal Medicine Publication of Study Showing 20 Percent of Heart Attack Patients in Premier Registry Experienced Angina at One Year
9. Pilot Therapeutics Announces Relaunch as Gene Smart(TM) Health
10. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
11. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 According to a ... Devices Market (Endoscopes, Endoscopic Operative Devices, and Visualization Systems) ... Forecast, 2013-2019" the global endoscopy devices market was valued ... to grow at a CAGR of 6.8% from 2013 ... 36.9 billion in 2019. Browse the full ...
(Date:7/10/2014)... , July 11, 2014  Major advances in ... cancer are being highlighted in a three-day Oncology ... from 10-12 July, 2014.  Renowned national and international cancer ... best practices and exchange knowledge on modern technologies ... and efficient. The Summit will ...
(Date:7/10/2014)... DIEGO , July 10, 2014  RESMED INC. (NYSE: ... its fourth quarter and fiscal year ended June 30, 2014 ... Stock Exchange market close. A press release with ResMed,s results ... the company will host a webcast to discuss operating results ... to begin at 1:30 p.m. US Pacific Time and the ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... Alere Inc. (NYSE: ALR ) announced today ... notes due 2018 through a private placement, subject to market ... from the offering for working capital and other general corporate ... commence immediately, will be to qualified institutional buyers in reliance ...
... (Nasdaq: PCYC ) today reported financial results for its ... During the fiscal year ended June 30, 2010, total ... in the fiscal year ended June 30, 2009.  The GAAP net ... $15.0 million, or $0.31 per share. This compares to a GAAP ...
Cached Medicine Technology:Alere Inc. Announces Offering of $350 Million of Senior Subordinated Notes 2Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 2Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 3Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 4Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 5Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 6Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 7Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 8Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 9Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 10Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 11Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 12Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 13Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 14
(Date:7/11/2014)... (PRWEB) July 11, 2014 Recently, iFitDress.com, ... special occasion outfits, has released its new collection of ... that, the company has announced that all these beautiful ... off. The deadline of the special offer is July ... its major officials pay close attention to customer satisfaction. ...
(Date:7/11/2014)... Organic Crop Farming in ... the limelight over the past decade. According to IBISWorld ... to be an alternative food eaten only by minority ... organic food.” Organic crop farmers have reaped the benefits ... and herbs over the past five years. Industry revenue ...
(Date:7/11/2014)... era of personalized medicine may be just around the ... researcher Min Yu and scientists at Massachusetts General Hospital ... study in Science , Yu and her colleagues ... the blood streams of six patients. Some of these ... travel to and establish secondary tumors in vital organs ...
(Date:7/11/2014)... Alliance Labs announced that they will be featured ... Jr, airing later this year 2014, via Discovery Channel. ... Innovations will explore DocuSol® Kids, a mini-enema containing a ... base designed to give adolescents general constipation relief. Viewers ... hyperosmotic laxative by drawing water into the bowel from ...
(Date:7/11/2014)... Cruciate Ligament (ACL) reconstructions occur more than 200,000 times ... create a new ligament may determine how long you ... today at the Annual Meeting of the American Orthopaedic ... study results highlight that in a young athletic population, ... than using autografts (tissue harvested from the patient)," said ...
Breaking Medicine News(10 mins):Health News:Worldwide Chic Ladies Can Buy Cheap Evening Dresses at iFitDress.com 2Health News:Organic Crop Farming in Australia Industry Market Research Report Now Available from IBISWorld 2Health News:Organic Crop Farming in Australia Industry Market Research Report Now Available from IBISWorld 3Health News:Organic Crop Farming in Australia Industry Market Research Report Now Available from IBISWorld 4Health News:Alliance Labs & DocuSol® to be Featured in Upcoming Episode of Innovations 2Health News:ACL reconstructions may last longer with autografts 2
... efforts to unlock therapeutic potential , , MONDAY, Feb. 9 ... Obama,s anticipated lifting of the eight-year ban on embryonic ... W. Bush. , The anticipation moved one step closer ... House Democrats at a closed-door Virginia retreat a "guarantee" ...
... Inc. (Nasdaq: BNVI ) announced today the ... company,s Scientific Advisory Board. Dr. Gustafsson has extensive experience ... biotech companies. "We are very excited to have Dr. ... advancing our discovery platforms," said Isaac Cohen, O.M.D., Bionovo,s ...
... Fla., Feb. 9 MEDai, Inc., a leading provider ... it is offering a free case study on its ... analytic solution Risk Navigator Clinical(R) and its,application to keep ... The case study explores how one of MEDai,s ...
... -- Mindray Medical,International Limited (NYSE: MR ... devices worldwide, today announced that it will report ... year ended December 31,2008, after the U.S. market ... an earnings conference call at 8:00 AM on ...
... during 2008 holiday shopping seasonFORT WORTH, Texas, Feb. 9 ... customers, raised nearly $1.5 million for the fifth-annual ... fundraising initiative for St. Jude Children,s Research Hospital that ... , Customers who shopped at RadioShack stores had the ...
... supplement is the real deal. Extreme Endurance is a 100% ... certified drug-free by the world,s largest sports drug laboratory. In a ... lactic acid was reduced by 15%. This was a 30 day ... ...
Cached Medicine News:Health News:Scientists Heartened at Prospect of End to Stem Cell Ban 2Health News:Scientists Heartened at Prospect of End to Stem Cell Ban 3Health News:Jan Ake Gustafsson, M.D., Ph.D., Joins Bionovo's Scientific Advisory Board 2Health News:Jan Ake Gustafsson, M.D., Ph.D., Joins Bionovo's Scientific Advisory Board 3Health News:Jan Ake Gustafsson, M.D., Ph.D., Joins Bionovo's Scientific Advisory Board 4Health News:Health Plans Use MEDai to Forecast, Rank Risk and Drive Interventions 2Health News:Mindray to Report Fourth Quarter and Fiscal Year 2008 Financial Results on March 4, 2009 2Health News:RadioShack Helps Raise $1.5 Million for St. Jude Children's Research Hospital(R) Fifth-Annual Thanks and Giving(R) Campaign 2Health News:RadioShack Helps Raise $1.5 Million for St. Jude Children's Research Hospital(R) Fifth-Annual Thanks and Giving(R) Campaign 3Health News:Nutritionist Investigates Claims of New Sports Nutritional Supplement 2Health News:Nutritionist Investigates Claims of New Sports Nutritional Supplement 3Health News:Nutritionist Investigates Claims of New Sports Nutritional Supplement 4Health News:Nutritionist Investigates Claims of New Sports Nutritional Supplement 5
Shepard tying forceps, round curved platform 8 mm, 8.5 cm....
Girard curved tying forceps made of titanium has curved shafts with 8 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 99 mm....
Girard straight tying forceps made of titanium has straight shafts with 6 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 105 mm....
Curved tying forceps made of titanium has curved shafts with 6 mm V-grove tying platforms, width of shafts 0,5 mm, TCI platforms, flat handle, width 10 mm, overall length 103 mm....
Medicine Products: